|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The clinical response to timely postsurgical RAI therapy is not inferior in BRAF(V600E) mutation PTC patients without distant metastases, which suggests that RAI therapy might improve the general clinical outcome in this patient group.
|
26780618 |
2016 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared with wild-type BRAF, the BRAF(V600E) mutation was associated with aggressive clinicopathological factors, including extrathyroidal extension, higher TNM stage, lymph node metastasis, and recurrence, and was associated with reduced overall survival; however, there was no significant association between the presence of BRAF mutation and distant metastasis.
|
27600854 |
2016 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated whether the presence of a BRAF V600E mutation is differentially associated with sites and appearance of metastatic disease in patients matched by primary tumor location.
|
27956538 |
2016 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was identified in 1% of patients only. p53 protein was lowly expressed in TGCT metastases compared to the matched primary tumors.
|
27085458 |
2016 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also observed a positive association between BRAF V600E and TERT C228T mutations in the cohort of DM-PTCs.
|
25583906 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
This is the largest study on the aggressive role of TERT promoter mutations in ATC, demonstrating an association of TERT C228T with BRAF V600E, older patient age, and tumor distant metastasis in ATC.
|
25584719 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investigated for sentinel node metastasis.
|
25442222 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Previous studies implicating aberrant AKT signaling in human melanoma metastases led us to evaluate the effect of activated AKT1 expression in non-metastatic BRAF(V600E)/Cdkn2a(Null) mouse melanomas in vivo.
|
26565903 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We present a case of a 56-year old woman with a history of stage IIIA malignant melanoma resected in 2004 that was diagnosed in May 2013 with BRAF V600E-mutated metastatic disease (left arm mass, lungs and adrenal glands).
|
25576527 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The higher incidence of p.V600E mutations in LNs may prompt further studies to elucidate if the p.V600E mutation in primary tumors is associated with a higher risk of LN metastasis.
|
25456393 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and 3D culture of BRAF(V600E) mutant cell lines derived from human papillary (BCPAP) and anaplastic (SW1736) thyroid carcinomas.
|
26384551 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study correlates histological features, immunoreactivity for CK19, HBME, and Gal, and BRAF V600E mutation with lymph node (LN) metastasis and follow-up in FVPTC.
|
25702102 |
2015 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) was characterized in 113 PTC patients diagnosed with pT1aNo-x (one PTC focus with a diameter <1 cm, without lymph node or distant metastases according to IUCC/AJCC TNM staging system 2010).
|
24354346 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.
|
25367198 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, RAF inhibitors paradoxically accelerate metastasis in RAS-mutant tumors and become ineffective in BRAF(V600E) tumors because of reactivation of downstream mitogen-activated protein kinase (MAPK) signaling.
|
25097033 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The utility of immunohistochemistry (IHC) as an alternative approach for detection of BRAF(V600E) in the thoracic metastases of sporadic mCRC patients has not been evaluated until now.
|
24798160 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
They include BRAF(V600E) and AKT that affect tumor initiation, progression and metastasis.
|
24362526 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Decreased Dicer gene expression in malignant tissues was correlated greatly with aggressive features: extrathyroidal extension, angiolymphatic invasion, multifocality, lymph node and distant metastasis, recurrence, and BRAF((V600E)) mutation.
|
25456905 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor microenvironment greatly differs between visceral metastasis and primary cutaneous melanoma, and the mechanisms involved in the antimetastatic efficacy of BRAF(V600E) inhibitors remain to be determined.
|
25351955 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas with their matched metastases (n = 42), recurrences (n = 9) and second primaries (n = 4) was performed.Nine patients had multiple metastases.
|
25236573 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
|
24888229 |
2014 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
All patients with lateral cervical node metastasis (n=9), and all but one tumor with extrathyroidal extension (n=17/18) showed BRAF(V600E) mutation.
|
22918165 |
2013 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
There were significant differences in clinicopathological parameters, such as extrathyroidal extension (P=0.031), nodal metastasis (P=0.021) and BRAF(V600E) mutation (P=0.039), between NF-κB-positive and negative PTCs.
|
23528368 |
2013 |
|
rs113488022
|
|
Neoplasm Metastasis
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E gene mutation was documented in this lesion, and the patient received vemurafenib, with dramatic improvement noted on positron emission tomography scan after 2 months of treatment, soon followed by development of extensive metastases, including to brain.
|
23715079 |
2013 |